230 related articles for article (PubMed ID: 34028061)
1. Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
Zhu S; Chen J; Ni Y; Zhang H; Liu Z; Shen P; Sun G; Liang J; Zhang X; Wang Z; Wei Q; Li X; Chen N; Li Z; Wang X; Shen Y; Yao J; Huang R; Liu J; Cai D; Zeng H
Prostate; 2021 Aug; 81(11):721-727. PubMed ID: 34028061
[TBL] [Abstract][Full Text] [Related]
2. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
[TBL] [Abstract][Full Text] [Related]
3. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.
Francini E; Gray KP; Shaw GK; Evan CP; Hamid AA; Perry CE; Kantoff PW; Taplin ME; Sweeney CJ
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):420-427. PubMed ID: 30643173
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
5. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
[TBL] [Abstract][Full Text] [Related]
7. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
8. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
Freedland SJ; Davis M; Epstein AJ; Arondekar B; Ivanova JI
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):327-333. PubMed ID: 37783836
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Thomas C; Brandt MP; Baldauf S; Tsaur I; Frees S; Borgmann H; Jäger W; Bartsch G; Schneider M; Dotzauer R; Neisius A; Haferkamp A
Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
[TBL] [Abstract][Full Text] [Related]
13. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Prostate stereotactic body radiotherapy for metastatic castration-resistant prostate cancer: A prospective cohort study.
Li J; Dai J; Xian P; Xiong L; Song Y; Tang X; Li Y; Wu Y; Zhou H; Liu N
Cancer Treat Res Commun; 2021; 27():100368. PubMed ID: 33848805
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
16. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
Patel DN; Howard LE; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen ZW; Terris MK; Freedland SJ
Cancer; 2020 Jul; 126(14):3274-3280. PubMed ID: 32374476
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study.
Takai M; Kato S; Nakano M; Fujimoto S; Iinuma K; Ishida T; Taniguchi M; Tamaki M; Uno M; Takahashi Y; Komeda H; Koie T
Asia Pac J Clin Oncol; 2021 Jun; 17(3):238-244. PubMed ID: 32970933
[TBL] [Abstract][Full Text] [Related]
18. Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer.
Tashiro K; Kimura S; Tsuzuki S; Urabe F; Fukuokaya W; Mori K; Aikawa K; Murakami M; Sasaki H; Miki K; Miki J; Shimomura T; Yamada H; Hata K; Nishikawa H; Abe H; Watanabe K; Kimura T
Clin Genitourin Cancer; 2024 Jun; 22(3):102075. PubMed ID: 38643665
[TBL] [Abstract][Full Text] [Related]
19. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
20. Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.
Verry C; Vincendeau S; Massetti M; Blachier M; Vimont A; Bazil ML; Bernardini P; Pettré S; Timsit MO
Target Oncol; 2022 Jul; 17(4):441-451. PubMed ID: 35841526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
